enVVeno Medical Corporation (NASDAQ:NVNO – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 24,103 shares, an increase of 104.8% from the October 15th total of 11,771 shares. Based on an average daily volume of 39,897 shares, the days-to-cover ratio is presently 0.6 days. Currently, 4.1% of the company’s shares are sold short.
enVVeno Medical Stock Performance
enVVeno Medical stock traded down $0.29 during midday trading on Monday, reaching $5.88. The stock had a trading volume of 10,422 shares, compared to its average volume of 20,933. The stock’s 50-day simple moving average is $8.11 and its 200 day simple moving average is $10.09. enVVeno Medical has a twelve month low of $5.80 and a twelve month high of $14.66. The stock has a market capitalization of $4.05 million, a PE ratio of -0.35 and a beta of 1.41.
enVVeno Medical (NASDAQ:NVNO – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($6.29) EPS for the quarter, missing the consensus estimate of ($3.27) by ($3.02). Equities analysts predict that enVVeno Medical will post -16.19 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enVVeno Medical in a research report on Friday, September 25th. Wall Street Zen downgraded shares of enVVeno Medical from a “hold” rating to a “sell” rating in a research note on Sunday, November 1st. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.
Get Our Latest Research Report on enVVeno Medical
enVVeno Medical Company Profile
enVVeno Medical is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart. The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition.
Further Reading
- Five stocks we like better than enVVeno Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
